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the standard cytogenetics classiﬁcation (unfavorable, intermediate,
favorable). We then compared each of this subgroup with the
corresponding population of patients presenting the same risk
factors but owning a HLA identical sibling. In the standard risk
group (n  66), no-donor patients presented a favorable 10-year
survival (74%) compared with patients with a donor (51%) (P 
not signiﬁcant), and allo-SCT should not be recommended. In the
poor risk group (n  131), patients without a donor presented a
poor outcome (10-year OS  17%), which was not better if a
donor existed (28%) (P  .29); in these patients with a poor
outcome whatever the treatment, investigational studies should be
recommended. In the intermediate risk group (n  275), allo-SCT
offered a better outcome; the 10-year probabilities of relapse,
nonrelapse death, OS, and LFS (no donor vs donor) were 47%
versus 18% (P  .0001), 7% versus 17% (P  .02), 47% versus
63% (P  .02), and 45% versus 64% (P  .001), and the 10-year
OS was 56% versus 41% (P  .01). Allo-SCT represent a real
chance of long-term outcome and might beneﬁt from recent ad-
vances. We conclude that long-term outcome might be achieved in
some subgroups of patients and that the indication for allo-ASCT
could be assessed trough a simple classiﬁcation based on common
parameters.
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The most common reason for failure in later-stage patients after
allogeneic hematopoietic stem cell transplantation (allo-HSCT)
for AML and advanced MDS is leukemic relapse, demonstrating
the inability of preparative regimen to completely eradicate leuke-
mic cells. We report the outcome of allo-HSCT for myeloid
malignancies using myeloablative preparative regimen including
TBI and high-dose cytarabine. In addition, granulocyte colony-
stimulating factor (G-CSF) was simultaneously administered with
cytarabine to increase the susceptibility of leukemic cells to cytar-
abine. Patients and Methods: Patients with myeloid malignan-
cies, including AML, AML evolving from MDS, and advanced
MDS (RAEB, RAEB-t, CMML) were eligible. For conditioning,
patients received TBI (12 Gy) followed by intravenous high-dose
cytarabine (3g/m2 every 12 hours for 4 consecutive days). Recom-
binant G-CSF (lenograstim; 5 g/kg/day) was administered intra-
venously by continuous infusion for 4 days, starting 12 hours
before the ﬁrst dose of Ara-C and continued until the last dose of
Ara-C. For the prophylaxis of acute graft-versus-host disease, cy-
closporine A or tacrolimus with or without short-term methotrex-
ate was given. Results: Seventy-nine patients were evaluable, with
a median age of 39 years (range, 15–58 years). Their diagnoses
were AML in 57, AML from MDS in 11, and MDS in 11 (RAEB
in 8, RAEB-t in 1, CMML in 1). Five-year overall survival (OS),
disease-free survival (DFS), and relapse rate (RR) were 79.1%,
76.3%, and 15.2% in AML in remission, and 41.9%, 34.4%, and
46.4% in AML not in remission. These rates were 43.6%, 43.6%,
and 0% in AML from MDS and 71.6%, 72.7%, and 10% in
advanced MDS. For AML in remission, no risk factor affecting OS
and RR was observed, whereas both high-risk karyotype abnormal-
ity and high numbers of blasts in the peripheral blood negatively
affected OS, and these 2 factors and absence of chronic GVHD
signiﬁcantly increased RR in AML not in remission. Conclusions:
These data suggest that TBI and G-CSF combined high-dose
cytarabine is a highly effective regimen for allo-HSCT for AML in
remission, AML evolving from MDS, and advanced MDS with a
notably low incidence of relapse.
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EBV-associated Hodgkin’s disease (HD) and some cases of
non-Hodgkins lymphoma (NHL) show type II latency express-
ing the subdominant EBV antigens EBNA1, LMP1, and LMP2,
which may serve as targets for immunotherapy approaches. In
previous studies, we used polyclonal EBV-speciﬁc CTL in pa-
tients with relapsed EBVHD and saw 2 complete and 1 partial
responses in 11 patients. Analyses of EBV-CTL lines showed
that small populations of T cells reactive against the tumor-
associated antigen LMP2 were present in most of the infused
lines, with some expansion in the peripheral blood after infu-
sion. We therefore hypothesized that CTL speciﬁcally targeting
LMP2 might have greater efﬁcacy in these patients. LMP2-
CTLs were generated from 10 patients using dendritic cells and
lymphoblastoid cell lines (LCLs) that had been genetically mod-
iﬁed to overexpress LMP2 by transduction with an
Ad5f35LMP2 vector. Polyclonal LMP2-CTL lines recognized
2–6 (median, 4) LMP2 epitopes, as determined using overlap-
ping LMP2 peptide pools in ELISPOT assays. A mean of 22.8%
(range, 5%-42.1%) of CD8 T cells bound HLA-restricted
LMP2 tetramers, compared with a mean of 0.11% (range,
0.01%-0.24%) of LMP2-tetramer positive CD8 T cells found
in CTLs generated with genetically unmodiﬁed LCLs from the
same patients. So far, 6 patients have been treated with 2 doses
of 2  107 CTL/m2 2 weeks apart. No immediate toxicity was
observed. In patients with identiﬁed LMP2 epitopes, measure-
ment of IFN secretion by CD8 T cells after stimulation with
appropriate LMP2 peptides in ELISPOT assays showed a 4- to
25-fold increase in spot-forming cells after infusions. In con-
trast, frequencies of CMV and superantigen-speciﬁc T cells did
not increase. Four patients without radiologic evidence of dis-
ease who received CTL as adjuvant therapy post-SCT or che-
motherapy remain well up to 12 months post-CTL. Two pa-
tients with measurable disease at the time of CTL infusion had
stable disease 8 weeks post-CTL. They received 2 further doses
of LMP2-CTL. One patient continues with stable disease, and
the other patient had a complete radiologic response. This
patient had a supraclavicular lymph node resection that showed
selective accumulation of LMP2 tetramer-positive cells (0.3%,
compared to 0.01% in the peripheral blood) with few residual
tumor cells. Immunotherapy with autologous LMP2-CTL is
therefore well tolerated in patients with relapsed EBV HD/
NHL, and infused LMP2-CTL cells can localize to the tumor
and induce a clinical response.
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REPAIR OF CROHN’S DISEASE WITH EMBRYONIC STEM CELLS
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The primary objective of this work is to determine differentiation
and repair potential of murine embryonic stem cells (ES) in murine
Crohn’s disease (CD) model. Methods: Colitis was induced in
IL10/ knock-out mice using piroxicam. The colitis in this
model is patchy and progressive and leads to death unless rescue
therapy is provided. Enhanced yellow ﬂuorescent protein (EYFP)
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